# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | IHH HEALTHCARE BERHAD |
| Establishment Date | N/A |
| Headquarters Location | Kuala Lumpur, Malaysia |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | IHH Healthcare integrates advanced medical technologies and digital healthcare solutions, including pioneering Upright Photon Therapy in Asia and AI-powered diagnostic tools such as SenseCare Chest CT, Lunit INSIGHT MMG, and Annalise AI for imaging analysis. The Group has implemented a Clinical Risk Assurance Framework and a governance framework for ethical AI integration, alongside conducting clinical audits across multiple countries to ensure continuous quality improvement. Additionally, IHH fosters a culture of innovation through initiatives like the IHH Research and Innovation Grant and the use of AI video analytics to prevent patient falls. | IHH Healthcare has invested in advanced medical technologies including the launch of the Proton Therapy Centre at Mount Elizabeth Novena Hospital, the first private hospital in Southeast Asia to offer this treatment. The Group integrates artificial intelligence (AI) to improve disease diagnostics and employs digital healthcare applications such as MyHealth360 for patient health management and AI-driven bill estimates. The Group maintains a robust clinical governance framework supported by the International Clinical Governance Advisory Council and continuously reviews clinical quality indicators and serious reportable events to enhance patient safety and care quality. |
| Product Advantages | IHH Healthcare operates a diversified portfolio of over 140 healthcare facilities, including more than 80 hospitals across 10 countries, offering a full spectrum of integrated healthcare services from primary to quaternary care, including diagnostics, laboratory testing, and rehabilitation. The Group manages well-known healthcare brands such as Acibadem, Fortis, Gleneagles, Island, Mount Elizabeth, Pantai, and Parkway, and expands offerings with advanced tests like genomics and high-end diagnostics. It also leads in complex care and medical specialties, exemplified by the introduction of robot-assisted surgeries and advanced cancer treatment protocols. | IHH Healthcare offers a broad portfolio of healthcare services across over 80 hospitals in 10 countries, including specialized treatments such as CAR T-cell therapy, da Vinci Robotic Surgical System procedures, and Ethos radiotherapy for advanced cancer treatment. The Group's brands, including Mount Elizabeth, Parkway, Gleneagles, Pantai, Fortis Healthcare, and Prince Court, are recognized for clinical excellence and quality care. The laboratory and diagnostic business is a growing segment, conducting 96 million tests across four markets in the fiscal year. |
| Brand Recognition | IHH Healthcare is recognized as one of the world's most trusted healthcare services networks, with established brands that have strong reputations for clinical outcomes and quality care. The Group received multiple prestigious awards in 2024, including FinanceAsia Asia's Best Company Awards and Corporate Governance Asia's Asian Excellence Awards, highlighting leadership in investor relations, corporate governance, and financial management. Its brands, such as Acibadem, have received local accolades like the Brandverse Gold Award in Turkey, and the Group is noted for its thought leadership through platforms like the HealthcareInsider series. | IHH Healthcare is recognized as a leading private healthcare provider with strong brand presence in multiple markets. The Group's hospitals, such as Mount Elizabeth in Singapore, are known as top destinations for medical treatment. IHH received multiple accolades in 2023 including Institutional Investor's Asia Pacific Executive Team rankings, Time magazine's 'World's Best Companies', and the 'Most Outstanding Company in Singapore - Healthcare Sector' by Asiamoney Asia. The Group also won the Gold award in the 'Healthcare Institutions' category at the Brandverse Awards TÃ¼rkiye 2023. |
| Reputation Ratings | IHH Healthcare maintains robust governance and sustainability practices overseen by the Board and Sustainability Committee, integrating ESG risks into its Enterprise Risk Management framework and aligning with IFRS S2 climate-related disclosures. The Group has received the National Corporate Governance & Sustainability Awards (NACGSA) Excellence Award 2024 and is committed to environmental initiatives such as large-scale solar projects. It adheres to international clinical accreditation standards including Joint Commission International (JCI) and Malaysian Society for Quality in Health (MSQH), and promotes transparency and accountability through comprehensive investor relations policies and regular stakeholder engagement. | IHH Healthcare demonstrates strong commitment to sustainability and ESG integration, with a Sustainability Policy and governance structure overseen by the Board and Sustainability Committee. The Group received the Best ESG Reporting (Large Cap) award at the IR Magazine Awards South East Asia 2023 and has embedded sustainability into its Balanced Scorecard linked to remuneration. The Group adheres to international clinical quality standards and holds accreditations from bodies such as the Malaysian Society for Quality in Health (MSQH), Joint Commission International (JCI), and National Accreditation Board for Hospitals and Healthcare Providers (NABH) in India. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | At IHH, we are united by our shared commitment to touch lives and transform care for patients and communities worldwide. |
| Vision Statement | To be the world's most trusted healthcare services network |
| Core Values | Patients First, Integrity, Empathy, Teamwork, Excellence |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 24,383.0 | 20,935.0 | 17,988,687.0 | Millions | RM |
| Cost of Goods Sold | (6,861.0) | (5,361.0) | (5,497,553.0) | Millions | RM |
| Gross Profit | 17,522.0 | 15,574.0 | 12,491,134.0 | Millions | RM |
| Operating Expense | (5,590.0) | (4,660.0) | (10,704,163.0) | Millions | RM |
| Operating Income | 11,932.0 | 10,914.0 | N/A | Millions | RM |
| Net Profit | 3,162.0 | 3,391.0 | 1,645,142.0 | Millions | RM |
| Income before income taxes | 3,756.0 | 4,049.0 | 2,217,091.0 | Millions | RM |
| Income tax expense(benefit) | (594.0) | (658.0) | (571,949.0) | Millions | RM |
| Interest Expense | (1,065.0) | (941.0) | (657,413.0) | Millions | RM |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | N/A | N/A | N/A | N/A | N/A |
| Current Assets | N/A | N/A | N/A | N/A | N/A |
| Non-Current Assets | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Non-Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Shareholders' Equity | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Total Equity and Liabilities | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A |
| Prepaid Expenses | N/A | N/A | N/A | N/A | N/A |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | N/A | N/A | N/A | N/A | N/A |
| Net Cash Flow from Investing | N/A | N/A | N/A | N/A | N/A |
| Net Cash Flow from Financing | N/A | N/A | N/A | N/A | N/A |
| Net Increase/Decrease in Cash | N/A | N/A | N/A | N/A | N/A |
| Dividends | N/A | N/A | N/A | N/A | N/A |


## S2.4: Key Financial Metrics

|       | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Profit Margin | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A |
| Debt-to-Equity | N/A | N/A | N/A |
| Interest Coverage | N/A | N/A | N/A |
| Asset Turnover | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Effective Tax Rate | N/A | N/A | N/A | 
| Dividend Payout Ratio | N/A | N/A | N/A |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | N/A | N/A | N/A |
| Revenue by Geographic Region | N/A | N/A | N/A |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | N/A |
| Operating Efficiency | N/A |
| External & One-Off Impact | N/A |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | N/A | N/A |
| Profitability and earnings quality | N/A | N/A |
| Operational efficiency | N/A | N/A |
| Financial risk identification and early warning | N/A | N/A |
| Future financial performance projection | N/A | N/A |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | N/A | N/A |
| Market Position | N/A | N/A |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | N/A | N/A |
| Operational Risks | N/A | N/A |
| Financial Risks | N/A | N/A |
| Compliance Risks | N/A | N/A |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| N/A | N/A | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | N/A | N/A |
| Control activities | N/A | N/A |
| Monitoring mechanisms | N/A | N/A |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | N/A | N/A |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | N/A | N/A |
| New technologies | N/A | N/A |
| Organisational Restructuring | N/A | N/A |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | N/A | N/A |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | N/A | N/A |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | N/A | N/A |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | N/A | N/A |
